Age-related macular degeneration
Treatment of age-related macular degeneration
Where staffing capacity allows, Mynzepli pre-filled syringes are the preferred first choice.
Aflibercept
Mynzepli 3.6mg/90microlitres solution for injection pre-filled syringes
Dose
Specialist advice.
Eylea 21mg/184microlitres solution for injection pre-filled syringes
Dose
Specialist advice.
Ranibizumab
Ranibizumab 2.3mg/0.23ml solution for injection vials
Dose
Specialist advice.
Faricimab
Vabysmo 21mg/0.175ml solution for injection pre-filled syringes
Dose
Specialist advice.
Vabysmo 28.8mg/0.24ml solution for injection vials
Dose
Specialist advice.
Prescribing Notes:
- Vascular endothelial growth factor inhibitors (aflibercept, faricimab and ranibizumab) are included on the formulary for the treatment of neovascular (wet) age-related macular degeneration (AMD). Vascular endothelial growth factor inhibitors are only to be administered by specialists experienced in the management of diabetic macular oedema.
History Notes
26/02/2026
Prescribing information update ERWG December 25.
10/04/2025
Updates to prescribing information, ERFC April 25.
27/02/2025
Update to prescribing information, ERFC Feb 25.
08/11/2023
Update to pathway and addition of Faricimab SMC2512, ERWG July 23
03/10/2023
Addition of Vabysmo 28.8mg/0.24ml solution for injection vials , ERWG July 23